Bank of America just raised its EUR/USD forecast
Investing.com - JPMorgan maintained its Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) but adjusted its price target to $30.00, down from its previous target of $40.00. The stock, which has seen a significant decline of about 48% over the past six months, currently maintains a strong "Buy" consensus among analysts with targets ranging from $14 to $51.
The price target adjustment follows Edgewise’s second-quarter 2025 results and recent data updates, with JPMorgan shifting to what it describes as a "more conservative approach" to its risk-adjusted valuation of sevasemten in neuromuscular indications. According to InvestingPro data, the company maintains a strong financial position with more cash than debt and a robust current ratio of 28.9x, providing significant operational runway.
JPMorgan has specifically removed Duchenne muscular dystrophy (DMD) value from its model as it awaits "further visibility on the path to the clinic" for this indication, which the firm believes will take time to better understand.
The new price target is now set for December 2026, compared to the previous target which was for December 2025.
As part of these changes, JPMorgan has removed Edgewise Therapeutics from its Analyst Focus List while maintaining its overall Overweight rating on the stock.
In other recent news, Edgewise Therapeutics reported a narrower-than-expected loss for the second quarter of 2025, with a quarterly loss of $0.34 per share, surpassing analysts’ projections of a $0.42 per share loss. The company maintained a robust cash position of approximately $594 million as of June 30, 2025, supporting its ongoing clinical programs. RBC Capital has raised its price target for Edgewise Therapeutics to $49, maintaining an Outperform rating following the company’s earnings report. Meanwhile, Raymond (NSE:RYMD) James reiterated its Strong Buy rating with a $46 price target, emphasizing that key catalysts remain on schedule. Both firms noted the anticipated EDG-7500 Phase 2 CIRRUS-HCM Part D results expected in the fourth quarter of 2025. Earlier trial data showed promising efficacy, though concerns were raised about a potential atrial fibrillation signal in about 14% of patients. These developments reflect ongoing investor interest and analyst confidence in Edgewise Therapeutics’ future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.